株式会社極東書店トップ ＞ 商品一覧 ＞ Pandemic Medicine : Why the Global Innovation System Is Broken, and How We Can Fix It.
商品詳細
Pandemic Medicine : Why the Global Innovation System Is Broken, and How We Can Fix It.
・ISBN 978-1-62637-969-5 hard US$ 95.00
￥22,258.- (税込) ※（※）価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。
お気に入り
★★★
・ISBN 978-1-62637-971-8 paper US$ 27.50
￥6,442.- (税込) ※（※）価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。
お気に入り
★★★
| 著者・編者 | Ibata-Arens, Kathryn C., |
|---|---|
| シリーズ | Advances in International Political Economy |
| 出版社 | (Lynne Rienner, US) |
| 出版年月 | 2021.07 |
| ページ数 | 190 pp. |
| 言語 | ENG |
| ニュース番号 | ＜669-455＞ |
解説
Despite a century of advances in modern medicine, as well as the rapid development of Covid vaccines, the global pharmaceutical industry has largely failed to bring to market drugs that actually cure disease. Why?
And looking further... How can government policies stimulate investment in the development of curative drugs? Is there an untapped potential for "natural medicines" in new drug discovery? How have private-public sector partnerships transformed the ways we innovate? To what extent are medicinal plant biodiversity and human health codependent?
Addressing this range of increasingly critical questions, Kathryn Ibata-Arens analyses the rise and decline of the global innovation system for new drug development and proposes a policy framework for fast-tracking the implementation of new discoveries and preparing for future pandemics.
And looking further... How can government policies stimulate investment in the development of curative drugs? Is there an untapped potential for "natural medicines" in new drug discovery? How have private-public sector partnerships transformed the ways we innovate? To what extent are medicinal plant biodiversity and human health codependent?
Addressing this range of increasingly critical questions, Kathryn Ibata-Arens analyses the rise and decline of the global innovation system for new drug development and proposes a policy framework for fast-tracking the implementation of new discoveries and preparing for future pandemics.